9月26日，迈得医疗盘中上涨2.24%，截至10:24，报20.08元/股，成交2617.97万元，换手率0.80%，总市 值33.38亿元。 资金流向方面，主力资金净流入60.86万元，特大单买入0.00元，占比0.00%，卖出198.31万元，占比 7.58%；大单买入768.59万元，占比29.36%，卖出509.42万元，占比19.46%。 迈得医疗今年以来股价涨85.93%，近5个交易日涨8.48%，近20日涨2.08%，近60日涨30.05%。 截至6月30日，迈得医疗股东户数3805.00，较上期减少4.80%；人均流通股43684股，较上期增加 5.05%。2025年1月-6月，迈得医疗实现营业收入1.41亿元，同比减少14.75%；归母净利润604.51万元， 同比减少38.81%。 分红方面，迈得医疗A股上市后累计派现2.02亿元。近三年，累计派现9929.75万元。 机构持仓方面，截止2025年6月30日，迈得医疗十大流通股东中，华夏行业景气混合A（003567）位居 第四大流通股东，持股366.97万股，持股数量较上期不变。华夏远见成长一年持有混合A（016250）位 居第七大流通股东 ...

9月16日，迈得医疗涨5.79%，截至发稿，报20.66元/股，成交5664.83万元，换手率1.69%，总市值34.34 亿元。 资料显示，迈得医疗工业设备股份有限公司位于浙江省玉环市沙门镇滨港工业城，成立日期2003年3月 10日，上市日期2019年12月3日，公司主营业务涉及医用耗材智能装备的研发、生产、销售和服务。主 营业务收入构成为：安全输注类连线机42.18%，血液净化类连线机37.90%，安全输注类单机14.04%， 其他类5.87%。 从基金十大重仓股角度 数据显示，国泰基金旗下1只基金重仓迈得医疗。国泰聚利价值定期开放灵活配置混合（005746）二季 度持有股数20万股，占基金净值比例为1.08%，位居第八大重仓股。根据测算，今日浮盈赚取约22.6万 元。 程瑶累计任职时间4年71天，现任基金资产总规模19.21亿元，任职期间最佳基金回报14.74%， 任职期 间最差基金回报3.78%。 国泰聚利价值定期开放灵活配置混合（005746）成立日期2018年3月27日，最新规模2.73亿。今年以来 收益5.47%，同类排名6623/8174；近一年收益10.46%，同类排名6881/7982；成 ...

截至发稿，陈顾君累计任职时间5年241天，现任基金资产总规模2.04亿元，任职期间最佳基金回报 36.87%， 任职期间最差基金回报-7.57%。 数据显示，浙商证券资管旗下1只基金重仓迈得医疗。浙商汇金新兴消费（009527）二季度持有股数4.3 万股，占基金净值比例为2.79%，位居第七大重仓股。根据测算，今日浮盈赚取约4.86万元。 浙商汇金新兴消费（009527）成立日期2020年5月29日，最新规模2273.84万。今年以来收益18.39%，同 类排名4505/8174；近一年收益53.15%，同类排名2837/7982；成立以来收益15.9%。 浙商汇金新兴消费（009527）基金经理为陈顾君。 9月16日，迈得医疗涨5.79%，截至发稿，报20.66元/股，成交5669.63万元，换手率1.69%，总市值34.34 亿元。 资料显示，迈得医疗工业设备股份有限公司位于浙江省玉环市沙门镇滨港工业城，成立日期2003年3月 10日，上市日期2019年12月3日，公司主营业务涉及医用耗材智能装备的研发、生产、销售和服务。主 营业务收入构成为：安全输注类连线机42.18%，血液净化类连线机37.90%，安 ...

8月27日，迈得医疗跌5.07%，截至发稿，报19.47元/股，成交2.68亿元，换手率8.07%，总市值32.36亿 元。 融通健康产业灵活配置混合A/B（000727）基金经理为万民远。 资料显示，迈得医疗工业设备股份有限公司位于浙江省玉环市沙门镇滨港工业城，成立日期2003年3月 10日，上市日期2019年12月3日，公司主营业务涉及医用耗材智能装备的研发、生产、销售和服务。主 营业务收入构成为：安全输注类连线机42.18%，血液净化类连线机37.90%，安全输注类单机14.04%， 其他类5.87%。 从迈得医疗十大流通股东角度 数据显示，融通基金旗下1只基金位居迈得医疗十大流通股东。融通健康产业灵活配置混合A/B （000727）一季度减持156股，持有股数259.98万股，占流通股的比例为1.56%。根据测算，今日浮亏损 失约270.38万元。 融通健康产业灵活配置混合A/B（000727）成立日期2014年12月25日，最新规模20.74亿。今年以来收益 23.63%，同类排名3072/8194；近一年收益47%，同类排名2642/7963；成立以来收益198.7%。 责任编辑：小浪快报 截至发 ...

Core Viewpoint - The company, Maide Medical, is facing a significant decline in revenue and market challenges, particularly in its core safety infusion equipment segment, leading to concerns about its financial health and future prospects [2][3][4]. Revenue Performance - In 2024, Maide Medical's revenue plummeted by 42.77% year-on-year, totaling 275 million yuan, with core products experiencing substantial declines: safety infusion equipment revenue fell by 39.59%, and blood purification equipment revenue dropped to zero [2]. - The overall market for injection and puncture consumables in China shrank by 2.57% to 32 billion yuan, exacerbated by external pressures such as the FDA's safety reviews and tariffs on Chinese syringes [2]. Product Performance - The only bright spot was a 67.12% increase in revenue from blood purification connection machines, reaching 104 million yuan, although the average price halved from 20.78 million yuan to 8.01 million yuan [3]. - The shift towards lower-tier products in response to market demands raises concerns about the loss of technical premium and profitability [3]. Customer Concentration and Risks - The concentration of revenue among the top five customers increased, with the largest customer, Sanxin Medical, accounting for 32.65% of revenue (89.74 million yuan) and related transactions comprising 12.41% [3]. - The long repayment cycle of 1-3 years for major clients highlights potential liquidity risks for the company [3]. New Business Ventures - To counteract the decline in traditional business, Maide Medical is venturing into contact lens manufacturing through its subsidiary, Maide Shun, although this new business is currently in a cash-burning phase [4]. - Management expenses rose to 95 million yuan, and R&D expenses increased by 21.81% to 40 million yuan, with long-term loans of 30 million yuan fully invested in this new area [4]. Financial Health Indicators - Financial indicators are raising red flags, with inventory valued at 139 million yuan, constituting 22.99% of current assets, and a significant increase in contract liabilities by 78.59% to 98.84 million yuan [4]. - The company reported a goodwill impairment of 10.42 million yuan and a doubling of construction in progress to 50.01 million yuan, indicating potential asset bubble concerns [4].

Main Business - The company's main products include safety infusion devices and blood purification equipment, with significant revenue declines in safety infusion single machines and blood purification single machines, down 39.59% and 100.00% respectively, while blood purification continuous machines saw substantial growth [2][5][6] - The first major customer accounted for a significant portion of annual sales, with the increase in transaction amount attributed to the growth in the blood purification product business and the overall industry [2][14] Supplier Information - The company sources all standard parts externally, with a mix of self-manufactured, custom procurement, and outsourced processing for non-standard components. The total procurement amount for 2024 was 23,959.42 million yuan, a decrease of 36.99% compared to the previous year [28][29] Inventory and Contract Liabilities - The company reported that the inventory of blood purification single machines remained unsold due to production cycle delays and customer facility issues, impacting revenue recognition [11][12] - The company maintains a production model based on order fulfillment, which has led to fluctuations in sales revenue for blood purification single machines [11][12] Accounts Receivable and Long-term Receivables - The company provided details on its top five customers, including transaction amounts and payment conditions, indicating a healthy receivables situation with good recovery rates [13][15] Goodwill Impairment - There were no indications of impairment for the company's assets, as the net realizable value of blood purification single machines exceeded their costs, negating the need for inventory write-downs [12][25] Construction in Progress - The company has invested in the development of its contact lens manufacturing subsidiary, with a focus on material research and production line construction, indicating a strategic expansion into the optical sector [3][24] Market Trends - The blood dialysis medical device market in China is projected to grow steadily, with a compound annual growth rate of 5.67% from 2019 to 2023, expected to reach 51.515 billion yuan by 2030 [6][14] - The company is also expanding into the contact lens market, which is anticipated to grow significantly, with the transparent and colored contact lens markets projected to reach 161 billion yuan and 183 billion yuan respectively by 2030 [18][20]

Group 1 - The chairman and general manager of Maide Medical, Wang Yuling, increased her shareholding by 296,400 shares at an average price of 12.67 yuan, totaling 3.756 million yuan, bringing her total holdings to 494,300 shares [1][2] - Maide Medical's main business includes the manufacturing of molds, industrial automation control systems, laboratory analysis instruments, plastic products, industrial robots, and specialized machinery with independent functions, as well as software development and information system integration services [1] - As of December 31, 2024, the revenue breakdown for Maide Medical shows that safety infusion line machines generated 116 million yuan (42.18%), blood purification line machines 104 million yuan (37.90%), safety infusion single machines 38.6 million yuan (14.04%), and other revenues 16.1 million yuan (5.87%) [1] Group 2 - The latest market capitalization of Maide Medical is 2.254 billion yuan [2]

Group 1 - The chairman and general manager of Maide Medical, Wang Yuling, increased her shareholding by 195,900 shares at an average price of 11.59 yuan, totaling 2.2712 million yuan, resulting in a new holding of 197,800 shares [1][2] - Maide Medical's main business includes the manufacturing of molds, industrial automation control systems, laboratory analysis instruments, plastic products, industrial robots, and specialized machinery with independent functions, as well as software development and information system integration services [1] - As of December 31, 2024, the revenue breakdown for Maide Medical shows that safety infusion line machines generated 116 million yuan (42.18%), blood purification line machines 104 million yuan (37.90%), safety infusion single machines 38.6019 million yuan (14.04%), and other revenues 16.1469 million yuan (5.87%) [1] Group 2 - The latest market capitalization of Maide Medical is 1.961 billion yuan [2]

Company Performance - Maider Medical achieved an annual revenue of 275 million yuan with a comprehensive gross margin of 43.56% [1] - Revenue from blood purification and safe infusion line machines reached 104 million yuan and 116 million yuan, with gross margins of 51.81% and 39.44% respectively [1][3] - The company reported a 39.38% year-on-year increase in overseas revenue, totaling 17.63 million yuan, with a gross margin of 44.90%, surpassing domestic sales by 1.43 percentage points [3] R&D and Innovation - The company invested 40.41 million yuan in R&D, a 21.81% increase year-on-year, accounting for 14.70% of total revenue [1][5] - Maider Medical submitted 146 patent applications during the reporting period, including 21 invention patents, and received 78 new patent authorizations [5] - The company has a total of 416 authorized patents, including 195 invention patents, and has actively participated in drafting national and provincial standards [5][7] Market Position and Strategy - Maider Medical is recognized as a leading supplier of dialysis consumables and has maintained the highest market share in the industry for three consecutive years from 2021 to 2023 [3] - The company is focusing on expanding its product matrix in the contact lens business and has successfully obtained multiple medical device registration certificates [4] - The company aims to enhance its operational efficiency and expand its medical equipment industry chain by advancing its smart medical consumables project and technology center [4][6] Industry Trends - The global medical device market reached a size of 582.6 billion USD in 2023, growing by 5.40% year-on-year, while China's market exceeded 1 trillion yuan, reaching 1,032.8 billion yuan [2] - The medical device industry is transitioning towards high-quality development, driven by policy support, market expansion, and automation in production [2] - The company is positioned to leverage the opportunities presented by the aging population and the advancement of manufacturing strategies in China [1][2]